Gleevec News and Research

RSS
Gleevec is a drug used to treat different types of leukemia and other cancers of the blood, gastrointestinal stromal tumors, skin tumors called dermatofibrosarcoma protuberans, and a rare condition called systemic mastocytosis. It is also being studied in the treatment of other types of cancer. Gleevec blocks the protein made by the bcr/abl oncogene. It is a type of tyrosine kinase inhibitor. Also called imatinib mesylate and STI571.
Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Regorafenib able to control resistant gastrointestinal stromal tumor

Regorafenib able to control resistant gastrointestinal stromal tumor

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

PNAS: Ras proteins bring tension to the phosphate chain

PNAS: Ras proteins bring tension to the phosphate chain

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Fusion of FGFR and TACC gene leads to glioblastoma

Fusion of FGFR and TACC gene leads to glioblastoma

AB Science announces data from development program of masitinib in GIST

AB Science announces data from development program of masitinib in GIST

Beneficial design element in sunitinib phase III clinical trial for gastrointestinal stromal tumors

Beneficial design element in sunitinib phase III clinical trial for gastrointestinal stromal tumors

Longer looks: Rushed medicine; Exercising your way to a smarter brain

Longer looks: Rushed medicine; Exercising your way to a smarter brain

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

Modified imatinib cancer drug prevents morphine tolerance in rats

Modified imatinib cancer drug prevents morphine tolerance in rats

FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgery

FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgery

Novartis' Gleevec receives FDA approval for use in patients with CD117-positive GIST

Novartis' Gleevec receives FDA approval for use in patients with CD117-positive GIST

Kedem commences development of Gleevec to treat CML in children and adults

Kedem commences development of Gleevec to treat CML in children and adults

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

CytRx reports net loss of $0.6 million for third quarter 2011

CytRx reports net loss of $0.6 million for third quarter 2011

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Medco announces new offerings within Advanced Oncology Solutions

Medco announces new offerings within Advanced Oncology Solutions